<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36635930</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2212-4012</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Recent patents on biotechnology</Title><ISOAbbreviation>Recent Pat Biotechnol</ISOAbbreviation></Journal><ArticleTitle>Patent and Marketing Exclusivities 101 for Drug Developers.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>270</EndPage><MedlinePgn>257-270</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1872208317666230111105223</ELocationID><Abstract><AbstractText>Despite an ever-increasing need for newer, safer, more effective, and more affordable therapies to treat a multitude of diseases and conditions, drug development takes too long, costs too much, and is too uncertain to be undertaken without the conferment of exclusionary rights or entry barriers to motivate and sustain investment in it. These entry barriers take the form of patents that protect intellectual property and marketing exclusivity provisions that are provided by statute. This review focuses on the basic ins and outs of regulatory and patent exclusivities for which new chemical entities (NCEs), referring to never-before approved drugs with an entirely new active ingredient, are eligible and uses RRx-001, a small molecule aerospace-derived NCE in development for the treatment of cancer, radiation toxicity, and diseases of the NLR family pyrin domain containing 3 (NLRP3) inflammasome, as a "real world" example. This is intended as a '101-type' of primer; its aim is to help developers of original pharmaceuticals navigate the maze of patents, other IP regulations, and statutory exclusivities in major markets so that they can make proper use of them.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oronsky</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>EpicentRx, Torrey Pines, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caroen</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>EpicentRx, Torrey Pines, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brinkhaus</LastName><ForeName>Franck</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>EpicentRx, Torrey Pines, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reid</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>EpicentRx, Torrey Pines, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stirn</LastName><ForeName>Meaghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>EpicentRx, Torrey Pines, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Raj</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>EpicentRx, Torrey Pines, San Diego, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Recent Pat Biotechnol</MedlineTA><NlmUniqueID>101309942</NlmUniqueID><ISSNLinking>1872-2083</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010330" MajorTopicYN="N">Patents as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040541" MajorTopicYN="N">Marketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="Y">Azetidines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NLRP3 inhibitor</Keyword><Keyword MajorTopicYN="N">Patents</Keyword><Keyword MajorTopicYN="N">RRx-001</Keyword><Keyword MajorTopicYN="N">anticancer</Keyword><Keyword MajorTopicYN="N">radioprotection</Keyword><Keyword MajorTopicYN="N">regulatory exclusivities</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest, financial or otherwise.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>13</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36635930</ArticleId><ArticleId IdType="pmc">PMC10242760</ArticleId><ArticleId IdType="doi">10.2174/1872208317666230111105223</ArticleId><ArticleId IdType="pii">BIOT-EPUB-128740</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Surh Y.J. The 50-year war on cancer revisited: Should we continue to fight the enemy within? J. Cancer Prev. 2021;26(4):219&#x2013;223. doi: 10.15430/JCP.2021.26.4.219.</Citation><ArticleIdList><ArticleId IdType="doi">10.15430/JCP.2021.26.4.219</ArticleId><ArticleId IdType="pmc">PMC8749321</ArticleId><ArticleId IdType="pubmed">35047447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkson I.V., Madej B., Stahlberg E.A. Accelerating therapeutics for opportunities in medicine: A paradigm shift in drug discovery. Front. Pharmacol. 2020;11:770. doi: 10.3389/fphar.2020.00770.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.00770</ArticleId><ArticleId IdType="pmc">PMC7339658</ArticleId><ArticleId IdType="pubmed">32694991</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier R. Drug patents: The evergreening problem. CMAJ. 2013;185(9):E385&#x2013;E386. doi: 10.1503/cmaj.109-4466.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.109-4466</ArticleId><ArticleId IdType="pmc">PMC3680578</ArticleId><ArticleId IdType="pubmed">23630239</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelijns A.C. Institute of Medicine (US) Committee on Technological Innovation in Medicine Technological Innovation: Comparing Development of Drugs, Devices, and Procedures in Medicine. Washington (DC): National Academies Press (US); 1989.</Citation><ArticleIdList><ArticleId IdType="pubmed">25057714</ArticleId></ArticleIdList></Reference><Reference><Citation>Berndt E.R., Nass D., Kleinrock M., Aitken M. Decline in economic returns from new drugs raises questions about sustaining innovations. Health Aff. 2015;34(2):245&#x2013;252. doi: 10.1377/hlthaff.2014.1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.2014.1029</ArticleId><ArticleId IdType="pubmed">25646104</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriiri G.K., Njogu P.M., Mwangi A.N. Exploring different approaches to improve the success of drug discovery and development projects: A review. Fut J Pharm Sci. 2020;6(1):27. doi: 10.1186/s43094-020-00047-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43094-020-00047-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronson J.K., Green A.R. Me too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists. Br. J. Clin. Pharmacol. 2020;86(11):2114&#x2013;2122. doi: 10.1111/bcp.14327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14327</ArticleId><ArticleId IdType="pmc">PMC7576625</ArticleId><ArticleId IdType="pubmed">32358800</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M., Choi M. The determinants of research and development investment in the pharmaceutical industry: focus on financial structures. Osong Public Health Res. Perspect. 2015;6(5):302&#x2013;309. doi: 10.1016/j.phrp.2015.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrp.2015.10.013</ArticleId><ArticleId IdType="pmc">PMC4677505</ArticleId><ArticleId IdType="pubmed">26730355</ArticleId></ArticleIdList></Reference><Reference><Citation>Beall R.F., Hollis A., Kesselheim A.S., Spackman E. Reimagining pharmaceutical market exclusivities: Should the duration of guaranteed monopoly periods be value based? Value Health. 2021;24(9):1328&#x2013;1334. doi: 10.1016/j.jval.2021.04.1277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2021.04.1277</ArticleId><ArticleId IdType="pubmed">34452713</ArticleId></ArticleIdList></Reference><Reference><Citation>Gronde T.V., Uyl-de Groot C.A., Pieters T. Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. PLoS One. 2017;12(8):e0182613. doi: 10.1371/journal.pone.0182613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182613</ArticleId><ArticleId IdType="pmc">PMC5559086</ArticleId><ArticleId IdType="pubmed">28813502</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan W.A., Wirtz V.J., Stephens P. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: A descriptive time series analysis. PLoS One. 2013;8(9):e74399. doi: 10.1371/journal.pone.0074399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0074399</ArticleId><ArticleId IdType="pmc">PMC3787029</ArticleId><ArticleId IdType="pubmed">24098644</ArticleId></ArticleIdList></Reference><Reference><Citation>Druss B.G., Marcus S.C., Olfson M., Pincus H.A. Listening to generic Prozac: Winners, losers, and sideliners. Health Aff. 2004;23(5):210&#x2013;216. doi: 10.1377/hlthaff.23.5.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1377/hlthaff.23.5.210</ArticleId><ArticleId IdType="pubmed">15371387</ArticleId></ArticleIdList></Reference><Reference><Citation>IQVIA Institute for Human Data Science Medicine Use and Spending in the US.. 2019.</Citation></Reference><Reference><Citation>Oronsky B., Reid T.R., Larson C., et al. REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer. Future Oncol. 2019;15(30):3427&#x2013;3433. doi: 10.2217/fon-2019-0317.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fon-2019-0317</ArticleId><ArticleId IdType="pubmed">31509028</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Goyal S., Kim M.M., et al. A Review of clinical radioprotection and chemoprotection for oral mucositis. Transl. Oncol. 2018;11(3):771&#x2013;778. doi: 10.1016/j.tranon.2018.03.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2018.03.014</ArticleId><ArticleId IdType="pmc">PMC5918142</ArticleId><ArticleId IdType="pubmed">29698934</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Scicinski J., Ning S., et al. RRx-001, A novel dinitroazetidine radiosensitizer. Invest. New Drugs. 2016;34(3):371&#x2013;377. doi: 10.1007/s10637-016-0326-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10637-016-0326-y</ArticleId><ArticleId IdType="pmc">PMC4859863</ArticleId><ArticleId IdType="pubmed">26841903</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Guo X., Wang X., et al. Discovery of RRx-001, a Myc and CD47 downregulating small molecule with tumor targeted cytotoxicity and healthy tissue cytoprotective properties in clinical development. J. Med. Chem. 2021;64(11):7261&#x2013;7271. doi: 10.1021/acs.jmedchem.1c00599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00599</ArticleId><ArticleId IdType="pubmed">34043360</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgensztern D., Rose M., Waqar S.N., et al. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br. J. Cancer. 2019;121(3):211&#x2013;217. doi: 10.1038/s41416-019-0504-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-019-0504-8</ArticleId><ArticleId IdType="pmc">PMC6738071</ArticleId><ArticleId IdType="pubmed">31231122</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., He H., Lin B., et al. RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cell. Mol. Immunol. 2021;18(6):1425&#x2013;1436. doi: 10.1038/s41423-021-00683-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00683-y</ArticleId><ArticleId IdType="pmc">PMC8166941</ArticleId><ArticleId IdType="pubmed">33972740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma M., Li G., Qi M., Jiang W., Zhou R. Inhibition of the inflammasome activity of NLRP3 attenuates HDM-induced allergic asthma. Front. Immunol. 2021;12:718779. doi: 10.3389/fimmu.2021.718779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.718779</ArticleId><ArticleId IdType="pmc">PMC8369415</ArticleId><ArticleId IdType="pubmed">34413860</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N., Wang Y., Wang X., Sun N., Gong Y.H. Pathway network of pyroptosis and its potential inhibitors in acute kidney injury. Pharmacol. Res. 2022;175:106033. doi: 10.1016/j.phrs.2021.106033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2021.106033</ArticleId><ArticleId IdType="pubmed">34915124</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang J., She J., Lin F., et al. RRx-001 exerts neuroprotection against LPS-induced microglia activation and neuroinflammation through disturbing the TLR4 pathway. Front. Pharmacol. 2022;13:889383. doi: 10.3389/fphar.2022.889383.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.889383</ArticleId><ArticleId IdType="pmc">PMC9020799</ArticleId><ArticleId IdType="pubmed">35462935</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Knox S., Cabrales P., Oronsky A., Reid T.R. Desperate times, desperate measures: The case for RRx-001 in the treatment of COVID-19. Semin. Oncol. 2020;47(5):305&#x2013;308. doi: 10.1053/j.seminoncol.2020.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2020.07.002</ArticleId><ArticleId IdType="pmc">PMC7341953</ArticleId><ArticleId IdType="pubmed">32718560</ArticleId></ArticleIdList></Reference><Reference><Citation>Jurgensen K.J., Skinner W.K.J., Oronsky B., et al. RRx-001 Radioprotection: Enhancement of survival and hematopoietic recovery in gamma-irradiated mice. Front. Pharmacol. 2021;12:676396. doi: 10.3389/fphar.2021.676396.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.676396</ArticleId><ArticleId IdType="pmc">PMC8100686</ArticleId><ArticleId IdType="pubmed">33967816</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B., Caroen S., Abrouk N., Reid T.R., Reid T.R. RRx-001 and the right stuff: Protection and treatment in outer space. Life Sci. Space Res. 2022;35:69&#x2013;75. doi: 10.1016/j.lssr.2022.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lssr.2022.05.001</ArticleId><ArticleId IdType="pubmed">36336372</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrales P., Caroen S., Oronsky A., et al. The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury. Expert Rev. Hematol. 2017;10(6):575&#x2013;582. doi: 10.1080/17474086.2017.1324779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2017.1324779</ArticleId><ArticleId IdType="pmc">PMC8051333</ArticleId><ArticleId IdType="pubmed">28448172</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurgula O. Strategic patenting by pharmaceutical companies should competition law intervene? IIC Int. Rev. Ind. Prop. Copyr. Law. 2020;51(9):1062&#x2013;1085. doi: 10.1007/s40319-020-00985-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40319-020-00985-0</ArticleId><ArticleId IdType="pmc">PMC7592140</ArticleId><ArticleId IdType="pubmed">33132411</ArticleId></ArticleIdList></Reference><Reference><Citation>VSPTO. United States Patent and Trade Mark Office.
Available from: . www.uspto.gov</Citation></Reference><Reference><Citation>Shear R.H., Kelley T.E. A researchers guide to patents. Plant Physiol. 2003;132(3):1127&#x2013;1130. doi: 10.1104/pp.103.022301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1104/pp.103.022301</ArticleId><ArticleId IdType="pmc">PMC526265</ArticleId><ArticleId IdType="pubmed">12857793</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrini C.J., Majumder M.A., McGuire A.L. Persistent confusion and controversy surrounding gene patents. Nat. Biotechnol. 2016;34(2):145&#x2013;147. doi: 10.1038/nbt.3470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3470</ArticleId><ArticleId IdType="pmc">PMC5094359</ArticleId><ArticleId IdType="pubmed">26849516</ArticleId></ArticleIdList></Reference><Reference><Citation>N. Am. Vaccine, Inc. v. Am. Cyanamid Co., 7 F.3d 1571, 1577 (Fed. Cir. 1993).</Citation></Reference><Reference><Citation>WTO. TRIPS and pharmaceutical patents: Obligations
and exception. 2006.  Available from:  http://www.wto.org/english/tratop_e/trips_e/factsheet
_pharm02_e.htm#art31.</Citation></Reference><Reference><Citation>Konski A.F., Wu L.X. Inventorship and authorship. Cold Spring Harb. Perspect. Med. 2015;5(11):a020859. doi: 10.1101/cshperspect.a020859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a020859</ArticleId><ArticleId IdType="pmc">PMC4632863</ArticleId><ArticleId IdType="pubmed">26253091</ArticleId></ArticleIdList></Reference><Reference><Citation>Storz U. International intellectual property strategies for therapeutic antibodies. MAbs. 2011;3(6):596&#x2013;606. doi: 10.4161/mabs.3.6.17788.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/mabs.3.6.17788</ArticleId><ArticleId IdType="pmc">PMC3242846</ArticleId><ArticleId IdType="pubmed">22123063</ArticleId></ArticleIdList></Reference><Reference><Citation> Available from:  https://www.wipo.int/pct/en/pct_
contracting_states.html.</Citation></Reference><Reference><Citation>Taubman A. The international patent system and biomedical research: reconciling aspiration, policy and practice. AAPS J. 2008;10(4):526&#x2013;536. doi: 10.1208/s12248-008-9049-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-008-9049-0</ArticleId><ArticleId IdType="pmc">PMC2628210</ArticleId><ArticleId IdType="pubmed">18989789</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemley M., Sampat B. Is the patent office a rubber stamp? Emory Law J. 2008;58:181&#x2013;203.</Citation></Reference><Reference><Citation>CArdenas-Navia J. Thirty Years of Flawed Incentives: an Empirical and Economic Analysis of Hatch-Waxman Patent-Term Restoration. Berkeley Technol. Law J. 2015;29(2)</Citation></Reference><Reference><Citation>Taylor L.S., Braun D.E., Steed J.W. Crystals and crystallization in drug delivery design. Mol. Pharm. 2021;18(3):751&#x2013;753. doi: 10.1021/acs.molpharmaceut.0c01157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c01157</ArticleId><ArticleId IdType="pubmed">33594892</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Regulatory classification of pharmaceutical co-crystals guidance for industry. 2018.</Citation></Reference><Reference><Citation>Clark L., Beadle D. Patent term extensions: Issues, challenges and implications for pharmaceuticals. Pharm. Pat. Anal. 2012;1(4):427&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">24236881</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox S, Cannizzo L, Warner K, Wardle R, Velarde S, Ning S, Bednarski M.D. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof. WO2007022225A2. 2007</Citation></Reference><Reference><Citation>Robinson MK, Morin MJ. CH3 domain epitope tags. WO2019222575. 2019</Citation></Reference><Reference><Citation>Oronsky B, Caroen S, Reid TR., Carter C. Medication infusion devices, systems, and methods. WO2019241276. 2019 doi: 10.4155/ppa.12.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/ppa.12.47</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar Bandaru R., Rout S.R., Kenguva G., et al. Re-cent advances in pharmaceutical cocrystals: From bench to market. Front. Pharmacol. 2021;12:780582. doi: 10.3389/fphar.2021.780582.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.780582</ArticleId><ArticleId IdType="pmc">PMC8632238</ArticleId><ArticleId IdType="pubmed">34858194</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg R.S. Lecture: patents, product exclusivity, and information dissemination: How law directs biopharmaceutical research and development. Fordham Law Rev. 2003;72(3):477&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">14968794</ArticleId></ArticleIdList></Reference><Reference><Citation>Diependaele L., Cockbain J., Sterckx S. Raising the barriers to access to medicines in the developing world - the relentless push for data exclusivity. Developing World Bioeth. 2017;17(1):11&#x2013;21. doi: 10.1111/dewb.12105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dewb.12105</ArticleId><ArticleId IdType="pmc">PMC5347964</ArticleId><ArticleId IdType="pubmed">26818105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingham R.F., Castle G.H. Data and market exclusivity for pharmaceuticals in the European Community. Food Drug Law J. 2000;55(2):209&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">12269365</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R., Shah N.D., Ross J.S. Generic drugs in the United States: Policies to address pricing and competition. Clin. Pharmacol. Ther. 2019;105(2):329&#x2013;337. doi: 10.1002/cpt.1314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1314</ArticleId><ArticleId IdType="pmc">PMC6355356</ArticleId><ArticleId IdType="pubmed">30471089</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration, HHS. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule. Fed. Regist. 2008;73(164):49603&#x2013;49610.</Citation><ArticleIdList><ArticleId IdType="pubmed">18958946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesselheim A.S., Sinha M.S., Avorn J. Determinants of market exclusivity for prescription drugs in the United States. JAMA Intern. Med. 2017;177(11):1658&#x2013;1664. doi: 10.1001/jamainternmed.2017.4329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2017.4329</ArticleId><ArticleId IdType="pubmed">28892528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannappan S., Darrow J.J., Kesselheim A.S., Beall R.F. The timing of 30 month stay expirations and generic entry: A cohort study of first generics, 2013 2020. Clin. Transl. Sci. 2021;14(5):1917&#x2013;1923. doi: 10.1111/cts.13046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13046</ArticleId><ArticleId IdType="pmc">PMC8504843</ArticleId><ArticleId IdType="pubmed">33982425</ArticleId></ArticleIdList></Reference><Reference><Citation>Darrow J.J., Kesselheim A.S. Incentivizing Antibiotic Development: Why isn&#x2019;t the generating antibiotic incentives now (GAIN) act working? Open Forum Infect. Dis. 2020;7(1):ofaa001. doi: 10.1093/ofid/ofaa001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa001</ArticleId><ArticleId IdType="pmc">PMC6986775</ArticleId><ArticleId IdType="pubmed">32016125</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Qualified Infectious Disease Product Designation
Questions and Answers Guidance for Industry. 2008.  Available from:  https://www.fda.gov/files/
drugs/published/Qualified-Infectious-Disease-
Product-Designation-Questions-and-Answers.pdf.</Citation></Reference><Reference><Citation>Seoane-Vazquez E., Rodriguez-Monguio R., Szeinbach S.L., Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J. Rare Dis. 2008;3:33. doi: 10.1186/1750-1172-3-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-3-33</ArticleId><ArticleId IdType="pmc">PMC2631478</ArticleId><ArticleId IdType="pubmed">19087348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J., Ross J.S., Kapczynski A. Pediatric exclusivity and regulatory authority. JAMA. 2018;319(1):21&#x2013;22. doi: 10.1001/jama.2017.16477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.16477</ArticleId><ArticleId IdType="pubmed">29117365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr K.W., Henry T.C., Miller K.L. Is the priority review voucher program stimulating new drug development for tropical diseases? PLoS Negl. Trop. Dis. 2018;12(8):e0006695. doi: 10.1371/journal.pntd.0006695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006695</ArticleId><ArticleId IdType="pmc">PMC6103519</ArticleId><ArticleId IdType="pubmed">30092022</ArticleId></ArticleIdList></Reference><Reference><Citation>Articles 67(2) and 67 bis of the Japanese Patent Act, Articles 14, 14 quater and 77 bis of the PMD Act; see also Notification from the Director of Division of Economy, Health Policy Bureau No. 0605001 2009.</Citation></Reference><Reference><Citation>Kondo H., Masamune K. Effectiveness of drug post-marketing all-case surveillance as a safety measure in Japan. Ther. Adv. Drug Saf. 2021:12. doi: 10.1177/20420986211065215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20420986211065215</ArticleId><ArticleId IdType="pmc">PMC8689626</ArticleId><ArticleId IdType="pubmed">34987750</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitou H., Nakatani D., Myoui A., Kubota T., Ozono K. Pediatric drug development in Japan: Current issues and perspectives. Clin. Pediatr. Endocrinol. 2020;29(1):1&#x2013;7. doi: 10.1297/cpe.29.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1297/cpe.29.1</ArticleId><ArticleId IdType="pmc">PMC6958521</ArticleId><ArticleId IdType="pubmed">32029968</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel A. In this world nothing can be said to be certain, except death and taxes(tm) Benjamin Franklin, 1789. Colorectal Dis. 2012;14(4):399&#x2013;400. doi: 10.1111/j.1463-1318.2012.03001.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1463-1318.2012.03001.x</ArticleId><ArticleId IdType="pubmed">22390145</ArticleId></ArticleIdList></Reference><Reference><Citation>Nass S.J., Madhavan G., Augustine M.R., editors. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Ensuring Patient Access to Affordable Drug Therapies. Making Medicines Affordable: A National Imperative. Washington, DC: National Academies Press (US); 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">29620830</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker D.E. High drug prices: So who is to blame? Hosp. Pharm. 2017;52(1):5&#x2013;6. doi: 10.1310/hpj5201-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1310/hpj5201-5</ArticleId><ArticleId IdType="pmc">PMC5278914</ArticleId><ArticleId IdType="pubmed">28179734</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlin D.I. Staving off death: A case study of the pharmaceutical industry&#x2019;s strategies to protect block-buster franchises. Food Drug Law J. 2008;823:824&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">19601385</ArticleId></ArticleIdList></Reference><Reference><Citation>Glasgow L.J. Stretching the limits of intellectual prop-erty rights: Has the pharmaceutical industry gone too far? The J Law And Technol. 2001;232-33:237&#x2013;238.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>